Therapy Areas: Autoimmune
Merck KGaA initiates Phase III trial for oral cladribine in gMG
29 August 2024 - German science and technology company Merck KGaA (ETR:MRK) said on Thursday that it has commenced a Phase III clinical trial to evaluate the efficacy and safety of oral cladribine for...
ImmPACT Bio USA's IMPT-514 IND application receives US FDA approval
22 August 2024 - Clinical-stage biopharmaceutical company ImmPACT Bio USA Inc. (ImmPACT Bio) announced on Wednesday that it has received approval from the United States Food and Drug Administration (F...
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
12 August 2024 - Biopharmaceutical company Pfizer Inc (NYSE: PFE) on Monday reported encouraging top-line results from a Phase 3 clinical trial evaluating its ABRYSVO vaccine for respiratory syncytial...
IASO Biotherapeutics' Eque-cel IND application for two autoimmune disease indications receives US FDA approval
12 August 2024 - China-based biopharmaceutical company IASO Biotherapeutics announced Monday that the US Food and Drug Administration (FDA) has approved the investigational new drug (IND) application ...
Merck acquires Curon's CN201 for USD700m upfront
9 August 2024 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Friday that it has agreed to acquire CN201, a clinical-stage bispecific an...
Precision BioSciences partner TG Therapeutics receives IND clearance for azer-cel
9 August 2024 - Gene editing company Precision BioSciences Inc (Nasdaq:DTIL) announced on Friday that its partner TG Therapeutics has received US Food and Drug Administration (FDA) Investigational New...